NASDAQ: DNTHDianthus Therapeutics Inc Stock
$23.42+0.18 (+0.77%)
Updated Apr 23, 2024
DNTH Price
$23.42
Fair Value Price
$24.45
Market Cap
$687.30M
52 Week Low
$6.58
52 Week High
$33.77
P/E
-2.77x
P/B
4.07x
P/S
18.97x
PEG
N/A
Dividend Yield
N/A
Revenue
$2.83M
Earnings
-$43.56M
Gross Margin
100%
Operating Margin
-1,541.22%
Profit Margin
-1,541.2%
Debt to Equity
0.06
Operating Cash Flow
-$37M
Beta
1.12
Next Earnings
May 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A
DNTH Overview
Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how DNTH scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
DNTH ($23.42) is undervalued by 4.22% relative to our estimate of its Fair Value price of $24.45 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
DNTH ($23.42) is not significantly undervalued (4.22%) relative to our estimate of its Fair Value price of $24.45 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
DNTH is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more DNTH due diligence checks available for Premium users.
Be the first to know about important DNTH news, forecast changes, insider trades & much more!
DNTH News
Valuation
DNTH fair value
Fair Value of DNTH stock based on Discounted Cash Flow (DCF)
Price
$23.42
Fair Value
$24.45
Undervalued by
4.22%
DNTH ($23.42) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
DNTH ($23.42) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
DNTH is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
DNTH price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.77x
Industry
16.46x
Market
41.92x
DNTH price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.07x
Industry
5.93x
DNTH is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
DNTH's financial health
Profit margin
Revenue
$457.0k
Net Income
-$10.6M
Profit Margin
-2,311.4%
DNTH's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
DNTH's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$179.4M
Liabilities
$10.5M
Debt to equity
0.06
DNTH's short-term assets ($177.45M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
DNTH's short-term assets ($177.45M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
DNTH's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
DNTH's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$11.9M
Investing
-$8.2M
Financing
-$4.9M
DNTH's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
DNTH vs Biotech Stocks
Dianthus Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.